comparemela.com

Page 7 - Shefali Agarwal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Onxeo S A : Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector

Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategy at Sanofi, join the Company's Board as independent members Regulatory

Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare

Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategy at Sanofi, join the Company’s Board as independent membersPARIS (BUSINESS WIRE) Regulatory News:Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), « Onxe.

Onxeo Announces the Appointment of Dr Shefali Agarwal as the Company s Chairwoman of the Board

Onxeo Announces the Appointment of Dr Shefali Agarwal as the Company s Chairwoman of the Board
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Onxeo S A : Onxeo Reports Its 2021 Half-Yearly Financial Results and Provides an Update on Its Activities

Onxeo S A : Onxeo Reports Its 2021 Half-Yearly Financial Results and Provides an Update on Its Activities
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Onxeo S A : Onxeo: Report on the Combined General Meeting of June 10, 2021

Onxeo S.A.: Onxeo: Report on the Combined General Meeting of June 10, 2021 Shefali Agarwal, MD, a clinical development expert in oncology, is appointed Director of Onxeo Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), Onxeo », a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, announced that the Combined General Meeting held today in camera adopted all the resolutions presented, in accordance with the recommendations of the Board of Directors. The shareholders of the Company also renewed for three years the mandate of Mr. Thomas Hofstaetter, which expired at the end of this General Meeting and ratified the appointment of Mr. Julien Miara, representing Invus, to replace Mr. Jean-Pierre Kinet until the expiry of his mandate, at the end of the Meeting called to approve the accounts for the year ended December 31, 2021.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.